Patient-Oriented Research in Acute Lung Injury and Host Defense in the ICU

ICU 中以患者为中心的急性肺损伤和宿主防御研究

基本信息

项目摘要

Abstract: The overall goal of this new application for a Midcareer Investigator Award in Patient-Oriented Research is to enable Dr. Lee to build a research and mentoring program in patient-oriented research in acute lung injury and host defense. Acute lower respiratory traction infections (LRTI) in the ICU remains an enormous healthcare burden in the US and worldwide. LRTI remains a major cause of sepsis and risk factor for acute lung injury. Bacterial LRTI is also a frequent complication of acute lung injury that increases patient morbidity, length of stay and health-care costs. Dr. Lee is a physician scientist focused on broadening molecular understanding of critical illness syndromes such as acute lung injury by probing host-pathogen interplay to elucidate the biology of host factors that predispose individuals to pathogen-induced injury. This award will allow protected time for dedicated teaching, training, and mentoring of trainees that include junior faculty, fellows, residents, and medical students in translational research focusing on problems arising in critically ill patients. Specifically, mentoring will support novel investigations into acute lower respiratory tract infections from common Gram-negative bacterial pathogens in the ICU. The major hypothesis is that distinct molecular determinants of host-pathogen interplay identified at the bench provide unique insights into impairments of host defense mechanisms that associate with adverse clinical outcomes in the ICU. Two aims are proposed that leverage the unique capabilities of the investigator in translational research. Aim 1 will evaluate microbial factors that predispose patients to tissue inflammation and injury instigated by the Gram-negative pathogen Pseudomonas aeruginosa (PA) respiratory isolates in the ICU. We will test molecular pathways identified at the bench to explore the relationship between pathogen protease function to patient outcomes such as microbial persistence in the lower respiratory tract, ventilator-free days, length of stay and mortality. Aim 2 will evaluate impairments in host humoral immunity during critical illness and examine the relationship to patient outcomes including multiple organ dysfunction, mortality, acquisition of multi-drug resistant ICU infections, and serum killing of encapsulated Gram-negative pathogen Klebsiella pneumoniae. This K24 award will allow Dr. Lee to achieve two principal goals: (1) forge links between basic biology and medicine by probing host-pathogen interplay in the ICU setting and improve understanding of critical illness syndromes such as ARDS; and (2) to further develop her skills in mentoring trainees in patient-oriented research in molecular critical care while expanding her time devoted to mentoring. The successful execution of this award will enhance the productivity of both the K24 investigator and increase the pool of well-trained clinician investigators who are equipped to translate fundamental biology to the bedside and back.
摘要:这个新申请的总体目标是面向患者的职业中期研究者奖

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Janet Sojung Lee其他文献

Janet Sojung Lee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Janet Sojung Lee', 18)}}的其他基金

Evaluation of alternative complement activity within an ARDS cohort
ARDS 队列中替代补体活性的评估
  • 批准号:
    10038565
  • 财政年份:
    2020
  • 资助金额:
    $ 11.47万
  • 项目类别:
Patient-Oriented Research in Acute Lung Injury and Host Defense in the ICU
ICU 中以患者为中心的急性肺损伤和宿主防御研究
  • 批准号:
    10814680
  • 财政年份:
    2019
  • 资助金额:
    $ 11.47万
  • 项目类别:
Host control mechanisms against K. pneumoniae infection in the lungs
肺部肺炎克雷伯菌感染的宿主控制机制
  • 批准号:
    9532512
  • 财政年份:
    2018
  • 资助金额:
    $ 11.47万
  • 项目类别:
Infection as a risk factor for dementia: the role of CD36
感染作为痴呆症的危险因素:CD36 的作用
  • 批准号:
    10118704
  • 财政年份:
    2018
  • 资助金额:
    $ 11.47万
  • 项目类别:
Host control mechanisms against K. pneumoniae infection in the lungs
肺部肺炎克雷伯菌感染的宿主控制机制
  • 批准号:
    9913387
  • 财政年份:
    2018
  • 资助金额:
    $ 11.47万
  • 项目类别:
Mechanisms of host protection against pathogen-associated proteases in acute lung injury
急性肺损伤中宿主针对病原体相关蛋白酶的保护机制
  • 批准号:
    10231500
  • 财政年份:
    2017
  • 资助金额:
    $ 11.47万
  • 项目类别:
Mechanisms of host protection against pathogen-associated proteases in acute lung injury
急性肺损伤中宿主针对病原体相关蛋白酶的保护机制
  • 批准号:
    10478014
  • 财政年份:
    2017
  • 资助金额:
    $ 11.47万
  • 项目类别:
Mechanisms of host protection against pathogen-associated proteases in acute lung injury
急性肺损伤中宿主针对病原体相关蛋白酶的保护机制
  • 批准号:
    10898192
  • 财政年份:
    2016
  • 资助金额:
    $ 11.47万
  • 项目类别:
Enhancing Neutrophil Responses to Counter MDR Gram Negative Bacterial Pneumonia
增强中性粒细胞反应以对抗 MDR 革兰氏阴性细菌性肺炎
  • 批准号:
    8951695
  • 财政年份:
    2015
  • 资助金额:
    $ 11.47万
  • 项目类别:
Enhancing Neutrophil Responses to Counter MDR Gram Negative Bacterial Pneumonia
增强中性粒细胞反应以对抗 MDR 革兰氏阴性细菌性肺炎
  • 批准号:
    9089914
  • 财政年份:
    2015
  • 资助金额:
    $ 11.47万
  • 项目类别:

相似海外基金

Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8429041
  • 财政年份:
    2011
  • 资助金额:
    $ 11.47万
  • 项目类别:
Analysis of extravascular lung water dynamics and exhaustive evaluation of pulmonary epithelial metabolites to establish a novel therapeutic approach for acute lung injury/ acute respiratory distress syndrome
分析血管外肺水动力学和详尽评估肺上皮代谢物,以建立急性肺损伤/急性呼吸窘迫综合征的新治疗方法
  • 批准号:
    22592023
  • 财政年份:
    2010
  • 资助金额:
    $ 11.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
OBSERVATIONAL STUDY OF ACUTE LUNG INJURY & ACUTE RESPIRATORY DISTRESS SYNDROME
急性肺损伤的观察性研究
  • 批准号:
    7603766
  • 财政年份:
    2007
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8328484
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8328493
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8602427
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8844846
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8602351
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8654999
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
Treatment of Acute Lung Injury and Acute Respiratory Distress Syndrome
急性肺损伤和急性呼吸窘迫综合征的治疗
  • 批准号:
    8020428
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了